Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 12, 2013, Pages 7713-7718

  Thuong Lan, Vo Thi ^a   Thuan, Ta Bich ^a   Thu, Doan Minh ^a   Uyen, Nguyen Quynh ^a   Ha, Ngo Thi ^a   To, Ta Van ^b  

^a VIETNAM NATIONAL UNIVERSITY   (Viet Nam)

^b National Cancer Hospital   (Viet Nam)

Author keywords

Breast cancer 1 (BRCA1); Estrogen receptor (ER); RAS association domain family member 1 (RASSF1A)

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; ESTROGEN RECEPTOR; RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER STAGING; DNA METHYLATION; FEMALE; GENETICS; HUMAN; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; VIET NAM;

BRCA1 PROTEIN; DNA METHYLATION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; VIETNAM;

EID: 84893363233     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.12.7713     Document Type: Article

References (32)

1. Agathanggelou A, Honorio S, Macartney DP, et al (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 1509-8.
2. Asadollahi R, Hyde AC, Zhong XY (2010). Epigenetics of ovarian cancer: From the lab to the clinic. Gynecol Oncol, 118, 81-7.
3. Barnholtz-Sloan JS, Schwartz AG, Qureshi F (2003). Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol, 189, 1120-7.
4. Barton CA, Hacker NF, Clark SJ, Philippa M, O'Brien PM (2008). DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol Oncol, 109, 129-9.
5. BonDurant AE, Huang Z, Whitaker RS, et al (2011). Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol, 123, 581-7.
6. Clark SJ, Harrison J, Paul CL, Frommer M (1994). High sensitivity mapping of methylated cytosines. Nucleic Acids Res, 22, 2990-7.
7. de Caceres I, Battagli C, Esteller M, et al (2004). Tumor cellspecific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res, 64, 6476-1.
8. Du XL, Sun CC, Milam MR, Bodurka DC, Fang S (2008). Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer, 18, 660-9.
9. Esteller M, Silva JM, Dominguez G, et al (2000). Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst, 92, 564-70.
10. Esteller M, Corn PG, Baylin SB, Herman JG (2001). A gene hypermethylation pro?le of human cancer. Cancer Res, 61, 3225-9.
11. Feng S, Rubbi L, Jacobsen SE, Pellegrini M (2011). Determining DNA methylation profiles using sequencing. Methods Mol Biol, 733, 223-8.
12. Heichman KA, Warren JD (2012). DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med, 50, 1707-1.
13. Heyn H, Esteller M (2012). DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet, 13, 679-3.
14. Houshdaran S, Hawley S, Palmer C, et al (2010). DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE, 5, 9359.
15. Kristensen LS, Hansen L (2009). PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem, 55, 1471-3.
16. Lapidus RG, Nass SJ, Butash KA, et al (1998). Mapping of ER gene CpG island methylation by methylation-specific polymerase chain reaction. Cancer Res, 58, 2515-9.
17. Liu L, Yoon JH, Dammann R, Pfeifer GP (2002). Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogen, 21, 6835-1.
18. Mann M, Cortez V, Vadlamudi RK (2011). Epigenetics of estrogen receptor signaling: Role in hormonal cancer progression and therapy. Cancers, 3, 1691-7.
19. Mehrotra J, Ganpat MM, Kanan Y, et al (2004). Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res, 10, 2052-7.
20. Montavon C, Gloss BS, Warton K, et al (2012). Prognostic and diagnostic signi?cance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol, 124, 582-8.
21. Matoo AA, Khan H, Wani HA, et al (2013). RAS association domain isoform A gene (RASSF1A) hypermethylation in ovarian cancer patients of Kashmir Valley. J Pakistan Med Students, 3, 87-3.
22. Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N (2012). Methylation of tumor suppressor genes in ovarian cancer. Experimental and Therapeutic Medicine, 4, 1092-6.
23. Pan YM, Wu YZ, Shi YF, Zhu XQ (2010). Methylation of tumor suppressor gene RASSF1A and BRCA1 in primary epithelial ovarian cancer. Sci Res and Essays, 5, 3939-4.
24. Pathy NB, Hartman M, Yip CH, et al (2012). Ethnic differences in survival after breast cancer in South East Asia. PLoS ONE, 7, 30995.
25. Rathi A, Virmani AK, Schorge JO, et al (2002). Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res, 8, 3324-1.
26. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-9.
27. Teodoridis JM, Hall J, Marsh S, et al (2005). CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res, 65, 8961-7.
28. Widschwendter M, Jones A, TeschendorffAE (2013). Epigenetics makes its mark on women-speci?c cancers-an opportunity to rede?ne oncological approaches? Gynecol Oncol, 128, 134-3.
29. Wiencke JK (2004). Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer, 4, 79-4.
30. Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA (2005). High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogen, 159, 114-2.
31. Wiley A, Katsaros D, Chen H, et al (2006). Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovariantumors with low malignant potential. Cancer, 107, 299-8.
32. Zhang Q, Hu G, Yang Q, et al (2013). A multiplex methylationspecific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol, 130, 132-9.